Hospital
NYU Langone Hospitals
NYU Langone Hospitals was paid $117.59M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is J2350, Injection, ocrelizumab, 1 mg — 33% of everything it billed.
33Billing provider infoNYU LANGONE HOSPITALS
NEW YORK, NY 10016
NEW YORK, NY 10016
33aNPI1437230034assigned 10/18/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$117.59M
24GClaims691,088
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New York
Rank by total paid#3 of 33
Median peer was paid$171K
This provider vs. median689×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,080 | $217K | |
| 2019 | 40,713 | $6.45M | |
| 2020 | 101,613 | $15.28M | |
| 2021 | 129,954 | $20.52M | |
| 2022 | 142,072 | $25.30M | |
| 2023 | 150,156 | $29.47M | |
| 2024incomplete | 120,500 | $20.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | 33% | 1,467 | 1,322 | $39.25M |
| J9271 | Injection, pembrolizumab, 1 mg | 18% | 2,331 | 1,827 | $21.49M |
| J2323 | Injection, natalizumab, 1 mg | 6.1% | 1,224 | 1,174 | $7.14M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.8% | 20,568 | 13,657 | $3.35M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 2.3% | 713 | 447 | $2.74M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 16,945 | 14,182 | $2.56M |
| J9312 | Injection, rituximab, 10 mg | 2.1% | 430 | 306 | $2.51M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.0% | 1,662 | 976 | $2.36M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 26,764 | 10,470 | $2.15M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 1.8% | 302 | 200 | $2.10M |
| 96415 | 1.4% | 6,663 | 5,186 | $1.69M | |
| 77386 | 1.4% | 4,977 | 694 | $1.68M |
216 more codes
| J0897 | Injection, denosumab, 1 mg | 1.4% | 966 | $1.62M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.3% | 1,582 | $1.58M |
| 77412 | 1.2% | 4,111 | $1.44M | |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.1% | 495 | $1.32M |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 722 | $1.17M |
| 77336 | <1% | 3,678 | $1.13M | |
| J0485 | Injection, belatacept, 1 mg | <1% | 1,450 | $1.02M |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,369 | $909K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 355 | $855K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,979 | $784K |
| 80053 | Comprehensive metabolic panel | <1% | 56,713 | $777K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 177 | $773K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,042 | $595K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,882 | $579K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,847 | $567K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,421 | $538K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 3,014 | $535K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 28,549 | $480K |
| 76641 | <1% | 6,477 | $456K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 450 | $452K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 9,405 | $442K |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 292 | $440K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 90 | $419K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 114 | $414K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 217 | $400K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,582 | $380K |
| 96416 | <1% | 1,703 | $363K | |
| 36430 | <1% | 2,388 | $336K | |
| 31575 | <1% | 864 | $335K | |
| 77300 | <1% | 1,187 | $307K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 51,616 | $289K |
| 96417 | <1% | 4,570 | $281K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,561 | $277K |
| 77334 | <1% | 1,196 | $260K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 600 | $236K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,459 | $230K |
| 77066 | Tomosynthesis, mammo | <1% | 2,338 | $228K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 6,365 | $221K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,850 | $205K |
| 96409 | <1% | 1,949 | $192K | |
| 10005 | <1% | 487 | $190K | |
| 83615 | <1% | 15,224 | $170K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,011 | $160K |
| 77301 | <1% | 237 | $156K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,018 | $156K |
| 88185 | <1% | 707 | $153K | |
| 96367 | <1% | 2,904 | $144K | |
| 96411 | <1% | 2,225 | $140K | |
| 96401 | <1% | 1,715 | $137K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13,630 | $129K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,791 | $122K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,749 | $114K |
| 76642 | <1% | 2,192 | $114K | |
| 86850 | <1% | 5,074 | $110K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,106 | $106K |
| 77290 | <1% | 272 | $106K | |
| 93017 | <1% | 1,807 | $105K | |
| 96402 | <1% | 2,175 | $99K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 47,657 | $80K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 197 | $71K |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 40 | $71K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,320 | $71K |
| 36591 | <1% | 1,783 | $67K | |
| 77062 | <1% | 2,127 | $65K | |
| 77338 | <1% | 322 | $64K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 944 | $63K |
| 86901 | <1% | 5,089 | $58K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 2,098 | $56K |
| 77280 | <1% | 162 | $54K | |
| 82728 | <1% | 5,301 | $52K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 729 | $48K |
| 86945 | <1% | 1,818 | $44K | |
| 86900 | <1% | 5,093 | $43K | |
| 96523 | <1% | 1,007 | $42K | |
| 86480 | <1% | 783 | $41K | |
| 77061 | <1% | 1,271 | $40K | |
| 82378 | <1% | 3,072 | $39K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,749 | $39K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 281 | $37K |
| 77080 | <1% | 1,271 | $36K | |
| J3490 | Unclassified drugs | <1% | 2,486 | $35K |
| 87497 | <1% | 1,339 | $35K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 59 | $34K |
| 84703 | <1% | 8,451 | $32K | |
| 77332 | <1% | 194 | $32K | |
| 82784 | <1% | 2,016 | $31K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,933 | $31K |
| 83883 | <1% | 1,748 | $27K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14,156 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 413 | $26K |
| 86923 | <1% | 1,390 | $26K | |
| 71250 | <1% | 1,906 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,405 | $24K |
| 83735 | <1% | 5,651 | $23K | |
| 87799 | <1% | 426 | $22K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,103 | $21K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,739 | $21K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 162 | $21K |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 66 | $19K |
| 77049 | <1% | 63 | $19K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 608 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,753 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 659 | $17K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 9,640 | $17K |
| 88184 | <1% | 450 | $17K | |
| 82607 | <1% | 1,608 | $16K | |
| 84439 | <1% | 2,188 | $16K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 79 | $15K |
| 86334 | <1% | 1,147 | $15K | |
| 96377 | <1% | 633 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,514 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 774 | $14K |
| 86304 | <1% | 995 | $14K | |
| 99195 | <1% | 140 | $14K | |
| 88172 | <1% | 360 | $14K | |
| 82746 | <1% | 1,566 | $14K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,373 | $13K |
| 96368 | <1% | 860 | $13K | |
| 84100 | <1% | 3,794 | $12K | |
| 86300 | <1% | 819 | $12K | |
| 85730 | <1% | 2,364 | $11K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 326 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 115 | $11K |
| 86301 | <1% | 767 | $10K | |
| 83540 | <1% | 2,563 | $10K | |
| 85045 | <1% | 3,940 | $10K | |
| 88173 | <1% | 374 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,259 | $10K |
| 85610 | <1% | 2,602 | $10K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 5,835 | $9K |
| 83550 | <1% | 2,359 | $9K | |
| 84165 | <1% | 1,453 | $8K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 5,217 | $8K |
| 81003 | <1% | 4,368 | $8K | |
| 86769 | <1% | 327 | $8K | |
| 80061 | Lipid panel | <1% | 610 | $8K |
| 86140 | <1% | 2,279 | $8K | |
| 84153 | <1% | 667 | $7K | |
| 86803 | <1% | 869 | $7K | |
| 86706 | <1% | 919 | $7K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 444 | $7K |
| 77295 | <1% | 36 | $7K | |
| 86704 | <1% | 833 | $6K | |
| 85652 | <1% | 3,304 | $6K | |
| 80076 | <1% | 600 | $6K | |
| 90686 | <1% | 433 | $6K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 367 | $5K |
| 82948 | <1% | 1,633 | $5K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 155 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 274 | $5K |
| 86790 | <1% | 281 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,857 | $5K |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 144 | $4K |
| 87340 | <1% | 752 | $4K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 1,819 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 241 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 317 | $3K |
| G0008 | Administration of influenza virus vaccine | <1% | 230 | $3K |
| 83021 | <1% | 200 | $3K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 47 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 25 | $3K |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 158 | $3K |
| 99201 | <1% | 70 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 838 | $3K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 122 | $3K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 86 | $2K |
| 85670 | <1% | 550 | $2K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,325 | $2K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 246 | $2K |
| 82550 | <1% | 437 | $2K | |
| 36416 | <1% | 121 | $2K | |
| 85379 | <1% | 281 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 413 | $2K |
| 85240 | <1% | 121 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 80050 | General health panel | <1% | 89 | $1K |
| 83010 | <1% | 135 | $1K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 92 | $1K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 79 | $1K |
| 86160 | <1% | 83 | $1K | |
| 84702 | <1% | 91 | $1K | |
| 84156 | <1% | 384 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,081 | $1K |
| 84481 | <1% | 110 | $975.02 | |
| 84550 | <1% | 295 | $963.19 | |
| 85246 | <1% | 35 | $929.57 | |
| 82105 | <1% | 122 | $886.22 | |
| 80197 | <1% | 147 | $874.38 | |
| 82248 | <1% | 239 | $811.98 | |
| 88342 | <1% | 14 | $781.74 | |
| 90656 | <1% | 44 | $721.21 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28 | $690.19 |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | <1% | 31 | $650.88 |
| 84480 | <1% | 51 | $434.16 | |
| 85384 | <1% | 64 | $346.54 | |
| 90662 | <1% | 15 | $337.16 | |
| 84466 | <1% | 30 | $315.07 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 55 | $309.12 |
| 84403 | <1% | 13 | $296.82 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 59 | $278.87 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 226 | $213.39 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 105 | $210.08 |
| 85613 | <1% | 26 | $193.10 | |
| 85732 | <1% | 38 | $161.52 | |
| 85027 | <1% | 62 | $156.28 | |
| 81001 | <1% | 79 | $147.29 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 40 | $143.28 |
| 83690 | <1% | 33 | $141.55 | |
| 85303 | <1% | 12 | $107.75 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 26 | $91.90 |
| 85300 | <1% | 12 | $77.78 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 80 | $67.90 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 26 | $65.36 |
| 82150 | <1% | 16 | $63.61 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 139 | $50.62 |
| 77417 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, WESLEY (VP REVENUE CYCLE)
Parent organizationNYU LANGONE HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| NYU Langone Hospitals | Brooklyn, NY | $303.18M |
| NYU Langone Hospitals | New York, NY | $238.69M |
| NYU Langone Hospitals | Mineola, NY | $69.77M |
| NYU Langone Hospitals | New York, NY | $32.22M |
| NYU Langone Hospitals | New York, NY | $3.50M |
| NYU Langone Hospitals | Brooklyn, NY | $453K |
| NYU Langone Hospitals | Brooklyn, NY | $99K |
| NYU Langone Hospitals | Brooklyn, NY | $9K |
| NYU Hospitals Center | New York, NY | $55.44 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.